

What is claimed is:

1. A method for reducing a fat deposit *in vivo*, the method comprising contacting the fat deposit with an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, the fat deposit is a subcutaneous fat deposit or a visceral fat deposit, and the effective amount of the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.
5
2. The method of claim 1, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.
10
3. The method of claim 2, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.
15
4. The method of claim 1, wherein the contacting step is carried out by direct injection of the composition into the fat deposit.
5. The method of claim 4, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.
20
6. The method of claim 5, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.
7. The method of claim 4, wherein a volume of 25 μ L to 75 μ L of the composition is injected for each 0.5 cm³ to 1.0 cm³ of the fat deposit.
25
8. The method of claim 1, wherein the contacting step is carried out by injection of the composition into an interstitial space adjacent to the fat deposit.
30
9. The method of claim 8, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.

10. The method of claim 9, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

11. The method of claim 8, wherein a volume of 25 μ L to 75 μ l of the composition is injected for each 0.5 cm³ to 1.0 cm³ of the fat deposit.

12. The method of claim 1, wherein the fat deposit is a subcutaneous fat deposit and the contacting step is carried out by subcutaneous injection of the composition into or adjacent to the subcutaneous fat deposit.

13. The method of claim 12, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.

14. The method of claim 13, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

15. The method of claim 12, wherein a volume of 25 μ L to 75 μ l of the composition is injected for each 0.5 cm³ to 1.0 cm³ of the fat deposit.

16. A method for treating steatoblepharon in a subject, the method comprising identifying a subject in need of treatment for steatoblepharon and injecting into a fat deposit in an eyelid of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, and the effective amount of the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

17. The method of claim 16, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.

18. The method of claim 17, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.

19. The method of claim 16, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.

20. The method of claim 19, wherein the concentration of latanoprost is
5 1.0 mg/mL to 2.3 mg/mL.

21. The method of claim 16, wherein a volume of 25 μ L to 75 μ l of the composition is injected for each 0.5 cm³ to 1.0 cm³ of the fat deposit.

10 22. A method for treating proptosis in a subject, the method comprising identifying a subject in need of treatment for proptosis and injecting into an intraconal space of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, and the effective amount of the composition
15 reduces a number of adipocytes in the intraconal space by at least 35%.

23. The method of claim 22, wherein the proptosis is a result of thyroid-associated orbitopathy.

20 24. The method of claim 23, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.

25 25. The method of claim 24, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

26. The method of claim 22, wherein the subject suffers from Grave's disease or Hashimoto's thyroiditis.

30 27. The method of claim 26, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.

28. The method of claim 27, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

29. A method for treating obstructive sleep apnea associated with an excess upper airway fat in a subject, the method comprising identifying a subject in need of treatment for obstructive sleep apnea and injecting into an upper airway fat deposit of the subject an effective amount of a composition of latanoprost
5 encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, the effective amount of the composition reduces a number of adipocytes in the upper airway fat deposit by 5% to 90%.

10 30. The method of claim 29, wherein the upper airway fat deposit is located in the palate, the tongue, or the pharynx.

31. The method of claim 29, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.

15

31. The method of claim 30, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.

32. The method of claim 29, wherein a concentration of latanoprost in the
20 composition is 0.5 mg/mL to 3.0 mg/mL.

33. The method of claim 32, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.